{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:18:11Z","timestamp":1720689491756},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.3816\/clm.2009.s.038","type":"journal-article","created":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T21:03:00Z","timestamp":1255554180000},"page":"S382-S390","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S4","title":["Standard Management of Patients With Chronic Myeloid Leukemia"],"prefix":"10.3816","volume":"9","author":[{"given":"Carmen","family":"Fava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.038_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000065655","article-title":"Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia","volume":"108","author":"Barnes","year":"2002","journal-title":"Acta Haematol"},{"key":"10.3816\/CLM.2009.s.038_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2009.s.038_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.5858\/2006-130-669-IROAO","article-title":"Imatinib resistance: obstacles and opportunities","volume":"130","author":"Litzow","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.3816\/CLM.2009.s.038_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.038_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"10.3816\/CLM.2009.s.038_bib7","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.038_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.038_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.1999.17.1.284","article-title":"Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine","volume":"17","author":"Kantarjian","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.038_bib11","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib13","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.038_bib14","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib15","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V112.11.130.130","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib17","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.038_bib18","first-page":"375s","article-title":"Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure","volume":"26","author":"Hochhaus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.038_bib19","author":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology"},{"key":"10.3816\/CLM.2009.s.038_bib20","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLM.2009.s.038_bib22","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.038_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.038_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.onc.1209756","article-title":"Fusion tyrosine kinases: a result and cause of genomic instability","volume":"26","author":"Penserga","year":"2007","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2009.s.038_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib26","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib27","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2009.s.038_bib28","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.038_bib29","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib30","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib31","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.038_bib32","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib33","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib34","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V112.11.3225.3225","article-title":"Dasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.V112.11.3242.3242","article-title":"Dasatinib 100 mg once daily (QD) maintains long-term efficacy and minimizes the occurrence of pleural effusion: an analysis of 24-month data in patients with resistance, suboptimal response, or intolerance to imatinib (CA180-034)","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.038_bib36","first-page":"374s","article-title":"Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)","volume":"26","author":"Mauro","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.038_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.038_bib38","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2009.s.038_bib39","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib40","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib41","doi-asserted-by":"crossref","first-page":"100a","DOI":"10.1182\/blood.V110.11.319.319","article-title":"Molecular response according to type of preexisting BCR-ABL mutations after second line dasatinib therapy in chronic phase CML patients","volume":"110","author":"Mueller","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.s.038_bib43","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib44","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinibresistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib45","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V112.11.3238.3238","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib46","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V112.11.3229.3229","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study","volume":"112","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.038_bib47","first-page":"376s","article-title":"Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib","volume":"26","author":"Giles","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.038_bib48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V112.11.3216.3216","article-title":"Nilotinib efficacy according to baseline BCR-ABL mutations in patients with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP)","volume":"112","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib49","first-page":"401","article-title":"Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.038_bib50","first-page":"376s","article-title":"A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors","volume":"26","author":"Pinilla-Ibarz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.038_bib51","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF-1R\/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib52","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.038_bib53","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/mol.106.033308","article-title":"The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant Bcr\/Abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation","volume":"72","author":"Rahmani","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.3816\/CLM.2009.s.038_bib54","doi-asserted-by":"crossref","first-page":"316a","DOI":"10.1182\/blood.V110.11.1042.1042","article-title":"Simultaneous targeting of aurora kinases and Bcr-Abl by the small molecule inhibitor PHA-739358 is effective in imatinibresistant mutations including T315I","volume":"110","author":"Gontarewicz","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib55","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.leukres.2008.04.012","article-title":"PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases","volume":"32","author":"Gontarewicz","year":"2008","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2009.s.038_bib56","doi-asserted-by":"crossref","first-page":"312a","DOI":"10.1182\/blood.V110.11.1030.1030","article-title":"PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL","volume":"110","author":"Paquette","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib57","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib58","doi-asserted-by":"crossref","first-page":"276a","DOI":"10.1182\/blood.V110.11.907.907","article-title":"Phase IA\/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies","volume":"110","author":"Spencer","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib59","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-07-0835","article-title":"Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation","volume":"13","author":"Dasmahapatra","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.038_bib60","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib61","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cncr.21590","article-title":"Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy","volume":"106","author":"Borthakur","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib64","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.038_bib65","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib66","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V112.11.3239.3239","article-title":"Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib(IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation -results of an ongoing multicenter phase II study","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib67","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.038_bib68","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","article-title":"Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 Trial","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib69","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/leu.2008.7","article-title":"A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease","volume":"22","author":"Maslak","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.038_bib70","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.038_bib71","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib72","doi-asserted-by":"crossref","first-page":"318a","DOI":"10.1182\/blood.V106.11.1093.1093","article-title":"Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: rationale for combination tyrosine kinase inhibitor therapy","volume":"106","author":"Shah","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib73","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib74","first-page":"164a","article-title":"SGX70393 inhibits Bcr-AblT315I in vitro and in vivo and completely suppresses resistance when combined with nilotinib or dasatinib","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Ablexpressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib76","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib","volume":"105","author":"O'Hare","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CLM.2009.s.038_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood.V112.11.181.181","article-title":"High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Phpositive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party","volume":"112","author":"Rosti","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib78","first-page":"170","article-title":"Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CMLCP)","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib79","first-page":"74","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib80","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.038_bib81","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib82","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogenic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinb failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib83","doi-asserted-by":"crossref","first-page":"16a","DOI":"10.1182\/blood.V110.11.27.27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy","volume":"110","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib84","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.038_bib85","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.038_bib86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2009.s.038_bib87","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.038_bib88","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib89","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib90","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib91","first-page":"577a","article-title":"Event-free survival in patients (pts) with chronic myeloid leukemia (CML) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure is dependent on the in vitro sensitivity of BCR-ABL kinase domain (KD) mutations","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib92","first-page":"579a","article-title":"In vivo response to sequential tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) modeled based on in vitro properties of particular BCR-ABL kinase domain (KD) mutations","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.038_bib93","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T04:55:29Z","timestamp":1634014529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":93,"alternative-id":["S1557919011703663"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.038","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}